First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma

J Clin Rheumatol. 2021 Dec 1;27(8S):S877-S878. doi: 10.1097/RHU.0000000000001459.
No abstract available

MeSH terms

  • Antineoplastic Agents, Immunological* / adverse effects
  • Hodgkin Disease* / diagnosis
  • Hodgkin Disease* / drug therapy
  • Humans
  • Male
  • Neoplasm Recurrence, Local / drug therapy
  • Nivolumab / adverse effects

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab